

TRUSTEES' REPORT AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2024

THE UK MYELOMA
SOCIETY

MENZIES
BRIGHTER THINKING

THE UK MYELOMA SOCIETY

CONTENTS

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Trustees' Report	2 - 8
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11
Notes to the Financial Statements	12 - 21

Trustees' Annual Report for the period							
From	Period start date			To	Period end date		
	Day	Month	Year		Day	Month	Year
	1	April	2023		31	March	2024

Section A

Reference and administration details

Charity name	UK Myeloma Society
Other names charity is known by	UKMS
Registered charity number (if any)	1082702
Charity's principal address	Dr John Ashcroft, Treasurer Dept of Haematology Pathology building Pinderfields Hospital Mid Yorkshire Teaching NHS Trust Aberford Road Wakefield
Postcode	WF1 4DG

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1.	Dr Ceri Bygrave (Cardiff)	Chair from November 2023 Wales Representative	November 2023 – November 2025	
2.	Dr Neil Rabin (London)	Past Chair	November 2023 – November 2025	
3.	Dr John Ashcroft (Leeds, Mid Yorks)	Treasurer	November 2023 – November 2026	
4.	Dr Matthew Jenner (Southampton)	Secretary	November 2023 - November 2026	
5.	Dr Rachel Hall (Bournemouth)	Chair Elect	November 2023 -November 2025	
6.	Dr Jonathan Sive (London)	Education Lead	January 2023 -January 2026	
7.	Prof Gordon Cook (Leeds)	Dean of College of Myeloma	November 2019- on going	
8.	Prof Guy Pratt (Birmingham)	Board member	November 2023-November 2026	
9.	Prof Martin Kaiser (London)	Board member	January 2022 – January 2025	

10.	Dr Karthik Ramasamy (Oxford)	Communications Lead	June 2022 - June 2025	
11.	Dr Simon Stern (Surrey)	Guidelines Secretary	June 2020 - November 2024	
12.	Dr Rakesh Popat (London)	Science Lead	November 2021 - November 2024	
13.	Jackie Quinn (Belfast)	Myeloma Nurse Lead	November 2023 -November 2025	
14.	Dr Sarah Lawless (N.Ireland)	N.Ireland Representative (Invited Board member)	January 2021 -January 2024	
15.	Dr Jennifer Travers (Glasgow)	Scotland Representative (Invited Board member)	November 2023- November 2026	
16.	Dr Shelly Lawson (Sheffield)	Board member	November 2023 – November 2026	
17.	Catherine Loughran (Leicester)	Board member Pharmacy lead	November 2023-November 2025	
18.	Dr Sally Moore (Bath)	Board member	November 2023-November 2026	
19.	Sophie Castell (Myeloma UK)	Patient/Charity Representative	January 2018-ongoing	

Names of the trustees for the charity, if any, (for example, any custodian trustees)

Name	Dates acted if not for whole year

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address
Independent Examiner	Menzies LLP	Menzies LLP, Richmond House Walkern road, Stevenage, Herts, SG1 3QP
Bankers	Coutts & Co	440 Strand, London, WC2R 0QS

Name of chief executive or names of senior staff members (Optional information)

Section B Structure, governance and management

Description of the charity’s trusts

Type of governing document (eg. trust deed, constitution)	Constitution
How the charity is constituted (eg. trust, association, company)	Association

Trustee selection methods
(eg. appointed by, elected by)

Elected from membership

Additional governance issues (Optional information)

You **may choose** to include additional information, where relevant, about:

- policies and procedures adopted for the induction and training of trustees;
- the charity’s organisational structure and any wider network with which the charity works;
- relationship with any related parties;
- trustees’ consideration of major risks and the system and procedures to manage them.

Section C Objectives and activities

Summary of the objects of the charity set out in its governing document

The aims and objectives of the Society are to improve the treatment of patients with myeloma by:

- Developing and promoting clinical trials of myeloma treatment and linked scientific studies
- Encouraging collaborative research and innovation in myeloma
- Developing guidelines for the management of patients with myeloma
- Promoting knowledge through the education of healthcare professionals and patients in all aspects of the disease
- Promoting patient access to treatment through advocacy and working with stakeholders and partners

Summary of the main activities undertaken for the public benefit in relation to these objects (include within this section the statutory declaration that trustees have had regard to the guidance issued by the Charity Commission on public benefit)

The UKMS had a further active year in pursuit of its’ charitable objectives which are, education, research and advocacy.

To that end three Executive Committee meetings were held 2023; March, June and November.

In keeping with our objectives we have made significant progress in a number of key areas including educational meetings, guidelines and advocacy. The main activities undertaken to further its charitable purposes for the public benefit are detailed within this report. There are summarised in the following pages.

Additional details of objectives and activities (Optional information)

You **may choose** to include further statements, where relevant, about:

- policy on grantmaking;
- policy programme related investment;
- contribution made by volunteers.

<p>Revenue</p> <ul style="list-style-type: none">• Revenue received for corporate sponsorship contributed £123,800 (April 2023-March 2024). This re-enforces the support by pharma for the work that the UKMS undertakes. BMS supported the UKMS by awarding a corporate giving grant of £3,000 in 2024. This ore grant was to support mission and objectives received from Bristol Myers Squibb.• Separately, £33,000 was raised by Hartley Taylor Medical Communications Ltd from pharma (GSK, J&J, Sanofi x £10k + Amgen £3k) to support for the inaugural UKMRA Away Day on the 16-17 January 2024 in York.• In additional, £2,610 was raised from Pharma for the inaugural UKMS Pharmacy Education Day on the 23 November 2023 at the Wellcome Collection (Sanofi £500, Pfizer £1,500 and BMS £500 + £110 GSK). <p>Education</p> <p>The Autumn Day was held on 9th November 2023, as a hybrid meeting at the Cavendish Conference Centre and accessed on a virtual platform. The programme theme was ‘Myeloma Management – Beyond the Drugs’and featured Professor Heinz Ludwig from the Wilhelminen Cancer Research Institute in Vienna. He presented the Michael Morley Lecture on ‘Managing infections in the new era of myeloma therapies – prophylaxis, monitoring and treatment’.</p> <p>The Spring Day was also a hybrid meeting and was held on 20th March 2024. The theme for this meeting was the, ‘Controversies and Uncertainties – Unanswered Questions in Myeloma’. The plenary lecture was given by Professor Niels van der Donk from the Amsterdam University Medical Centre. His talk was entitled, ‘Bispecific Abs and CAR-T: sequencing, toxicities and practicalities’.</p> <p>Travel Bursaries</p> <p>A total of six travel bursaries for scientific conferences were awarded in 2023 to winning abstracts.</p> <ul style="list-style-type: none">• 2 x ASH San Diego £1,200 each• 2 x EHA Frankfurt £900 each• 2 X IMS Athens £900 each <p>The abstracts were presented at the subsequent Autumn / Spring Days in either November 2023 or March 2024. A corresponding conference report was also written by the bursary recipients from ASH, EHA and IMS which appeared in the UKMS e-newsletter.</p>

Section D Achievements and performance

Summary of the main achievements of the charity during the year

<p>25 years of the UKMS November 2023-24</p> <p>In November 2023, the Society began marking its 25 year anniversary. To communicate this, a unique 25 year logo was created and used on all communications throughout the year. A reception held at the Hope Street Hotel in Liverpool for UKMS members, speakers and stakeholders during the BSH Annual meeting on the 29 April 2024 where the Society was invited to host a joint symposium. (Venue and Catering - £1,940).</p>

Section D	Achievements and performance
	<p>Education: The annual meetings Production of two successful and well attended educational hybrid meetings in November 2023 and March 2024. For full programme details, please refer to the section above and the UKMS website.</p> <p>Travel Bursaries for scientific meetings The UKMS in collaboration with the Michael Morley Fund awarded 6 bursaries in 2023-24 to support the attendance of investigators, scientists, specialist nurses and pharmacists at ASH (American Society of Haematology), IMS (International Myeloma Society) and EHA (European Haematology Association) meetings in 2023-24. Further details can be found Section C.</p> <p>Advocacy The UKMS members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMS also help develop NICE clinical guidelines and more recently input into NHS England Algorithm.</p> <p>The Guidelines group The UKMS Guidelines Group, Chaired by Dr Simon Stern published in 2023 the MGUS good practice paper (GPP). Another GPP on smouldering myeloma was published early in 2024 in the British Journal of Haematology (BJH). GPPs on imaging in myeloma and high risk disease in transplant-eligible myeloma have been completed and accepted by the BSH Haem-onc Task Force and Guidelines Committee. They have both been submitted to the BJH for publication. The aim of the imaging GPP is to produce a document that reinforces the importance of functional imaging both at diagnosis and during the later management of myeloma patients.</p> <p>Other guidelines are work in progress, notably guidelines on the management of relapsed myeloma and a GPP on MGRS. Other guidelines in their early stages are on the management of myeloma bone disease and screening for amyloid in the outpatient setting.</p> <p>UKMRA - UK Myeloma Research Alliance The vision of the UKMRA, Chaired by Dr Rakesh Popat is that all UK based myeloma research is discussed within this forum to allow co-ordination of ideas and further development into national trials to maximise impact. The group met three times over the course of the year, twice virtually with one in-person/ hybrid meeting at the Wellcome Collection in central London on the 17th May 2023. On the 25 - 26 January 2024, the UKMRA held the first Away Day at the Principle Hotel in York. Around 30 clinical trial investigators from across the UK held their main group meeting as well as a full day dedicated to developing UK Myeloma related clinical trials.</p> <p>Myeloma Nurse Group Jackie Quinn took over as the Chair of the nurse group from Sarah Henshaw in November 2023. Projects and discussion for the 2023 included;</p> <ul style="list-style-type: none">• Develop protocol for Self-administration of Velcade.• Explored the potential for nurse webinars co-partnered with Myeloma UK.• Worked with Myeloma UK to produce a nurse network to support all haematology CNSs across the UK• Haematological Malignancies hybrid Nurse Study Day on 5 July 2023• In person Nurse Group meeting September 2023• The group were working with Tracey King, a Haematology nurse from Australia on adapting an online tool Myeloma treatment scheduler called ‘Mye Scheduler’ together the pharmacy group which is tailored to giving full visibility to patients.

Section D

Achievements and performance

Myeloma Pharmacy Group

The Pharmacy group, Chaired by Catherine Loughran will promote excellence in the pharmaceutical care of patients with myeloma and support, develop and encourage haematology pharmacists to undertake high quality, audit and research aligned with the UKMS work-plan, and aim to standardise clinical practice across the UK. There are 10 core members. On the 23 November 2023, the group held the first Annual Pharmacy Education Day at the Wellcome Collection in central London.

College of Myeloma (UK)

Prof Gordon Cook created the College of Myeloma (UK) in 2019. He remains the Dean of the College of Myeloma. The College consists of elected fellows representing those who have contributed significantly to the work of the UKMS and to patients with Myeloma through medical science, education and clinical care.

2023 fellows : Professor Ray Powles CBE
Dr Matthew Streetly
Professor Philippe Moreau

Section E

Financial review

Brief statement of the charity's policy on reserves

The UKMS's policy on its reserves is to maintain a sufficient level of funds to enable operating activities to be supported, taking account of potential risks and contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.

Details of any funds materially in deficit

Not applicable

Further financial review details (Optional information)

You **may choose** to include additional information, where relevant about:

- the charity's principal sources of funds (including any fundraising);
- how expenditure has supported the key objectives of the charity;
- investment policy and objectives including any ethical investment policy adopted.

Income

- Education Grants from Corporate Sponsors contributed approximately £123,800 in March 2023 - April 2024.
- Income from Pharmacy Day Sponsorship 23 November 2023 - £2,610
- A £12,000 charitable contribution was made to the UKMS from the Michael Morley fund in the year 23-24.
- UKMRA Away Day 16-17 January 2023, Principle Hotel in York Sponsorship revenue £33,000 (GSK, J&J, Sanofi x £10k + Amgen £3k)

The Michael Morley Fund

This fund is from a patient's estate that is invested on behalf of the UKMS. The Michael Morley funding can be used to fulfil our charitable objectives as agreed with the Michael Morley Trustees.

Expenditure

- Administrative costs (covering Executive meetings and associated expenses and the salary and on-costs of our Executive Manager, accountants' fees and employer's liability insurance). £36,000. Instucted new Accountants, Menzies annual fee £1,800+VAT

Educational meetings 2023-2024

- Spring and Autumn Education Days Approx £23,000
- UKMS Pharmacy Education Day 23 Nov 23 Wellcome Collection £1,974.60
- UKMRA f2f meeting 17 May 2024 at the Wellcome Collection £1,567.68

THE UK MYELOMA SOCIETY

INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 MARCH 2024

Independent Examiner's Report to the Trustees of The UK Myeloma Society ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 March 2024.

Responsibilities and Basis of Report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed:

Stuart Cuzner

Dated:

ACA FCCA

Menzies LLP Chartered Accountants

Richmond House, Walkern Road
Stevenage
SG1 3QP

THE UK MYELOMA SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2024

	Note	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Income from:				
Donations and legacies	3	130,667	130,667	131,251
Investments	4	6,850	6,850	5,775
Total income		137,517	137,517	137,026
Expenditure on:				
Raising funds	5	1,488	1,488	1,536
Charitable activities	7	116,069	116,069	94,941
Total expenditure		117,557	117,557	96,477
Net income before net gains/(losses) on investments		19,960	19,960	40,549
Net gains/(losses) on investments	12	15,674	15,674	(12,040)
Net movement in funds		35,634	35,634	28,509
Reconciliation of funds:				
Total funds brought forward		498,189	498,189	469,680
Net movement in funds		35,634	35,634	28,509
Total funds carried forward		533,823	533,823	498,189

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 12 to 21 form part of these financial statements.

THE UK MYELOMA SOCIETY

BALANCE SHEET
AS AT 31 MARCH 2024

	Note	2024 £	2023 £
Fixed assets			
Investments	12	199,044	191,492
		<u>199,044</u>	<u>191,492</u>
Current assets			
Debtors	13	-	2,799
Cash at bank and in hand		347,353	312,278
		<u>347,353</u>	<u>315,077</u>
Creditors: amounts falling due within one year	14	(12,574)	(8,380)
Net current assets		<u>334,779</u>	<u>306,697</u>
Total assets less current liabilities		<u>533,823</u>	<u>498,189</u>
Total net assets		<u>533,823</u>	<u>498,189</u>
Charity funds			
Designated funds	15	199,044	275,492
General funds	15	334,779	222,697
Total unrestricted funds	15	<u>533,823</u>	<u>498,189</u>
Total funds		<u>533,823</u>	<u>498,189</u>

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

DocuSigned by:

A7B83086CBD1420.....
Dr J Ashcroft
Trustee

Date: 30-Jan-2025

The notes on pages 12 to 21 form part of these financial statements.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

1. General information

UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the definition of a public benefit entity under FRS 102. The registered office is Pinderfields Hospital, Mid Yorkshire Teaching NHS Trust, Aberford Road, Wakefield, WF1 4DG.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

UK Myeloma Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

2.3 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Grants are included in the Statement of Financial Activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance Sheet. Where income is received in advance of entitlement, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Dividends arising on equity investments are accounted for in the year they are due and receivable.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

2. Accounting policies (continued)

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of Financial Activities.

2.7 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.8 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

2. Accounting policies (continued)

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Income from donations and legacies

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Donations	130,667	130,667	131,251
Total 2023	131,251	131,251	

4. Investment income

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Income from listed investments	5,366	5,366	5,351
Interest receivable	1,484	1,484	424
	6,850	6,850	5,775
Total 2023	5,775	5,775	

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

5. Investment management costs

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Investment management fees	1,488	1,488	1,536
Total 2023	1,536	1,536	

6. Analysis of grants

	Grants to Individuals 2024 £	Total funds 2024 £	Total funds 2023 £
Bursaries granted	6,000	6,000	7,666
Total 2023	7,666	7,666	

7. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2024 £	Total 2024 £	Total 2023 £
Forum expenses	69,941	69,941	45,907
Website costs	3,422	3,422	13,445
Bank charges	2,094	2,094	3,333
Staff costs (see note 10)	37,132	37,132	29,976
Accountancy (see note 9)	3,480	3,480	2,280
	116,069	116,069	94,941
Total 2023	94,941	94,941	

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

8. Analysis of expenditure by activities

	Activities undertaken directly 2024 £	Grant funding of activities 2024 £	Support costs 2024 £	Total funds 2024 £	Total funds 2023 £
Forum expenses	63,941	6,000	-	69,941	45,907
Website costs	3,422	-	-	3,422	13,445
Service charges	2,094	-	-	2,094	3,333
Staff costs (see note 10)	-	-	37,132	37,132	29,976
Accountancy (see note 9)	-	-	3,480	3,480	2,280
	<u>69,457</u>	<u>6,000</u>	<u>40,612</u>	<u>116,069</u>	<u>94,941</u>
<i>Total 2023</i>	<u>55,019</u>	<u>7,666</u>	<u>32,256</u>	<u>94,941</u>	

9. Independent examiner's remuneration

	2024 £	2023 £
Fees payable to the Company independent examiner for the independent examination of the Company's annual accounts	<u>3,480</u>	<u>2,280</u>

10. Staff costs

	2024 £	2023 £
Wages and salaries	36,357	29,049
Pension costs	775	927
	<u>37,132</u>	<u>29,976</u>

The average number of persons employed by the Charity during the year was as follows:

	2024 No.	2023 No.
Administration	<u>1</u>	<u>1</u>

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

10. Staff costs (continued)

No employee received remuneration amounting to more than £60,000 in either year.

Key management personnel are the trustees and they received no remuneration during the current or prior year.

11. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2023 - £NIL).

During the year ended 31 March 2024, expenses totalling £1,604 were reimbursed to 10 Trustees (2023 - £933 to 9 Trustees).

12. Fixed asset investments

	Listed investments £	Cash portfolio £	Total £
Cost or valuation			
At 1 April 2023	187,543	3,949	191,492
Additions	13,843	(13,843)	-
Disposals	(18,006)	18,316	310
Revaluations	15,364	-	15,364
Transfers	-	(12,000)	(12,000)
Management fees	-	(1,488)	(1,488)
Dividend and interest income	-	5,366	5,366
At 31 March 2024	198,744	300	199,044
Net book value			
At 31 March 2024	198,744	300	199,044
At 31 March 2023	187,543	3,949	191,492

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

13. Debtors

	2024 £	2023 £
Due within one year		
Other debtors	-	2,799
	-	2,799

14. Creditors: Amounts falling due within one year

	2024 £	2023 £
Trade creditors	-	6,150
Other taxation and social security	1,544	-
Pension fund loan payable	314	130
Other creditors	7,236	-
Accruals and deferred income	3,480	2,100
	12,574	8,380

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

15. Statement of funds

Statement of funds - current year

	Balance at 1 April 2023 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 March 2024 £
Designated funds						
Michael Morley Investment Fund	275,492	5,366	(1,488)	(96,000)	15,674	199,044
General funds						
General Funds	222,697	132,151	(116,069)	96,000	-	334,779
Total Unrestricted funds	498,189	137,517	(117,557)	-	15,674	533,823

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

15. Statement of funds (continued)

Statement of funds - prior year

	<i>Balance at 1 April 2022 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Gains/ (Losses) £</i>	<i>Balance at 31 March 2023 £</i>
Designated funds					
Michael Morley Investment Fund	283,717	5,351	(1,536)	(12,040)	275,492
General funds					
General Funds	185,963	131,675	(94,941)	-	222,697
Total Unrestricted funds	<u>469,680</u>	<u>137,026</u>	<u>(96,477)</u>	<u>(12,040)</u>	<u>498,189</u>

The designated fund is used to hold the Charity's investments and generate income.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

16. Analysis of net assets between funds

Analysis of net assets between funds - current period

	Unrestricted funds 2024 £	Total funds 2024 £
Fixed asset investments	199,044	199,044
Current assets	347,353	347,353
Creditors due within one year	(12,574)	(12,574)
Total	533,823	533,823

Analysis of net assets between funds - prior period

	Unrestricted funds 2023 £	Total funds 2023 £
Fixed asset investments	191,492	191,492
Current assets	315,077	315,077
Creditors due within one year	(8,380)	(8,380)
Total	498,189	498,189

17. Related party transactions

The Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 March 2024.